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MEDLINE Search Results
More than 4,000 eligible NHL patients have been treated with the CHOP chemotherapy as part of 43 different clinical trials identified that met the above criteria. Most patients formed part of trials aimed to treat patients with advanced disease (Ann Arbor stage I-II: 1,696 patients; stage III-IV: 2,584 patients) and with intermediate/high-grade NHL (3,783 patients). The dosages of prednisone and prednisolone vary among six different levels, as summarized below.
The First CHOP Combination
Gottlieb et al. [20] [1] [2] [3] [4] [5] . This is the first published article with the combination of this four-drug regimen that represents the CHOP chemotherapy regimen, although the dosages of these drugs were different from the trial that followed (SWOG 7204). The Eastern Cooperative Oncology Group (ECOG) and the Cancer and Leukemia Group B (CALGB), however, have always used this higher dose of prednisone in their CHOP trials. We should note that when this chemotherapy combination was first published as a preliminary report in an abstract form in Clinical Research in 1972 [21] , the dosages quoted for this combination were cyclophosphamide 600-900 
Level I: Prednisone 100 mg/day/days 1-5
Approximately 2,493 patients with NHL were treated with CHOP using a prednisone dose of 100 mg/day/days 1-5 as part of 21 different clinical trials. Two of the largest trials using this dose level are discussed below.
The excellent results obtained in a previous pilot study by Gottlieb et al . [20] led to the first large, prospective, randomized trial (SWOG trial 7204), using the CHOP chemotherapy regimen for NHL ( [22] . This is the study that most textbooks and published clinical trials using the CHOP program refer to as the source for the standard CHOP regimen and the first trial that uses the name CHOP to identify this chemotherapy combination. Five hundred and six patients with stage III and IV NHL were entered in this study. Patients were randomly assigned between CHOP (246 eligible patients/204 evaluable patients) and HOP (ADR, VCR, and prednisone); patients in complete remission after consolidation chemotherapy were then randomized to a maintenance chemotherapy program with either COP (CTX, VCR, and prednisone) or OAP (VCR, ARA-C, and prednisone).
One of the most important prospective clinical trials for patients with NHL was the national high-priority lymphoma study (Intergroup 0067; SWOG 8516; ECOG 3487) conducted between April 4, 1986, and June 15, 1991 [23] . In this study, 1,138 previously untreated patients with advanced disease were registered and 899 were found eligible. CHOP regimen with prednisone at 100 mg/day/days 1-5 (225 patients) was compared with the newer and more aggressive chemotherapy regimens known as m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone), ProMace-CytaBOM (prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytarabine, and bleomycin), and MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone). There has been no statistically significant difference in overall response rate, time to treatment failure, or overall survival among these four regimens. The CHOP regimen proved to be less toxic and less expensive. This study established CHOP as the gold standard for the treatment of NHL, and the regimen used as the benchmark for all new treatments.
The comparative analyses of these and the remainder of clinical trials using a CHOP regimen with prednisone at 100 mg daily for five days are summarized in [44] and ECOG 5477 trials [45] . In the original E6483 protocol [46] the investigators remark, "The combination COPA has been chosen as a control arm because of its demonstrated activity in previous ECOG studies. However, we have elected to employ Cyclophosphamide at a dose level of 750 mg/M 2 (rather than 600 mg/M 2 as in our previous studies). This dose level has been shown by others [24] to be well-tolerated."
Other clinical trials using this dose of prednisone are reviewed in Table 3 [53] . Another prospective randomized study conducted at Memorial Sloan-Kettering Cancer Center using six cycles of adjuvant CHOP after radiation therapy for pathologic stage I low and intermediate grade NHL also used a prednisone dose of 60 mg/m Stanford University published one of the very first trials with this dose. This study was conducted from June 1974 to May 1977 with 23 patients with diffuse histiocytic lymphoma. The treatment program was noted to be "as previously described by Coltman et al." [61] . The Novantrone (mitoxantrone) International Study Group, which conglomerated 14 countries in four different continents, ran a phase III study (7/84 to 10/87) comparing CHOP versus CN(novantrone)OP in 359 previously untreated patients with intermediate and high-grade NHL, stage II-IV. A total of 159 patients out of 263 eligible patients received CHOP [56] . Between November 1987 and October 1992, the British National Lymphoma Investigation (BNLI) group conducted a randomized comparison of PACE-BOM (Prednisone, ADR, CTX, VP 16, Bleomycin, VCR, and Methotrexate) versus "standard regimen" CHOP in patients with aggressive NHL. From a total of 459 eligible patients, 226 received CHOP with a prednisolone dose of 50 mg/m 2 /days 1-8. Although this CHOP regimen differs from the American programs, the authors acknowledged the difference and noted that this is the regimen that the BNLI was using since 1974 [55] . The results of other randomized clinical trials using this steroid dosage and conducted by the Lymphoma Group of Central Sweden [62] , the Swedish Lymphoma Study Group [56] , the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group [59] , the Dutch Hemato-Oncology Study Group [58] , and by the Grupo Argentino de Tratamiento de la Leucemia Aguda and Grupo Latinoamericano de Tratamiento de Hemopaties Malignas [63] are noted in Table 3 . (Table 3 ) [63] .
An additional single trial using a prednisone dosage of 60 mg daily for five days [66] was found but was not included for final analysis. (Tables 2 and 3 ). When analyzing patients treated with CHOP alone and receiving the two most frequently used dose levels of prednisone (levels I and II; Table 4), the mean complete response rates are 77.5% and 74.5% for levels I and II, respectively.
Advanced Stage
The largest group of patients treated with CHOP has been the one with advanced stage NHL. Approximately 35 clinical trials have been conducted using all six different levels of prednisone. When analyzing trials with a minimum of 50 Ann Arbor stage III and IV patients treated with at least six cycles of CHOP, the mean complete response rates are 54.75% and 54.5% for prednisone levels I and II, respectively (Table 4) . Table 5 shows the complete response rates and their calculated 95% confidence intervals for response rate data collected from trials that used CHOP for advanced aggressive NHL.
Survey
The eight-point questionnaire was sent via e-mail to 3,125 U.S. physicians from the 1999 ASCO directory book who met the selection criteria. The selection criteria used were unable to discern between physicians currently in clinical practice and taking care of NHL patients from those who did not. Six hundred and twenty-four (20%) e-mail messages were returned as "undeliverable mail." The major reasons were invalid e-mail addresses due to typographical errors in the directory and physicians changing e-mail addresses or no longer working for the institutions that own those e-mail addresses. Of the 2,501 physicians that we suspect have received the survey, 610 of them (24.4%) responded to the survey. One hundred and eighty-nine (7.5%) of them did not answer the questionnaire. Most frequent reasons cited for not answering were that they were not involved in the care of NHL patients, that they have already retired from active practice, or that they were involved in administrative or research activities at different biotechnology and pharmaceutical companies. Four hundred and twenty-one physicians completed the questionnaire.
Fifty-one percent (214/421) of physicians who responded to the survey have cared for more than 10 new cases of NHL in 1998 and 63% of them (263/421) treated at least five patients with CHOP during the same year. Thirty percent (127/421) of these practicing physicians were not aware of the existence of more than one prednisone dose schedule as part of the CHOP regimen. The three most frequent dosages being used are 100 mg/days 1-5 (67%), 100 mg/m 2 /days 1-5 (17%) Induction: average number of cycles = 7.6/patient Gomez [38] Induction: CHOP × 6 w/GM-G-CSF Epelbaum [40] Induction: stage III-IV, CHOP × 2 post-CR Okabe [41] Induction: CHOP × 6 w/rhG-CSF Meyer [42] Induction: CHOP × 6 (minimum) II Gordon [43] Induction: CHOP × 2→Response→CHOP × 6 Bezwoda [45] Induction: CHOP × 2 post-CR (minimum × 6) Zinzani [46] Induction: CHOP × 8-10 III Meyer [48] Induction:
Hagberg [54] Induction: CHOP × 9 (minimum) Sonneveld [55] Induction: CHOP × 6-8 Tirelli [56] Induction: CHOP × 6 VI Tagaki [60] Induction: CHOP up to 10 cycles Schaafsma [61] Induction: mean number of cycles = 6.0/patient Moreno, Colon-Otero, Solberg 245 and 60 mg/m 2 /days 1-5 (13%). Seventy-eight percent (330/421) write the prednisone dosage from "memory." Forty-seven percent declared that they observe a clinically significant incidence of steroid-related adverse events and 80% of them thought that these occur in more than 5% of the cases (26% considered it to affect more than 20% of treated patients). Hyperglycemia, weight gain, psychosis/depression, edema, and gastric intolerance are felt to occur in ≥20% of the time by 32%, 23%, 20%, 19%, and 15% of the surveyed physicians, respectively. A subset analysis of the 47% of physicians who responded that they observe a clinically significant incidence of steroid-related adverse events failed to reveal a direct correlation between adverse events and dose of steroid used.
DISCUSSION
Steroids are an integral part of most regimens against lymphoproliferative disorders. In the 1940s, studies with the then recently purified adrenotropic hormone and adrenal cortical hormone, showed the ability of steroids to decrease the normal and malignant lymphoid tissues of mice [67] [68] [69] . In the early 1950s the first reports of the effect of steroids in lymphoid tissue were published and large dose steroid therapy was initially used for the management of advanced stage lymphomas and leukemias [70, 71] . In 1961 Rosenberg et al. reported a complete review of 1,269 cases of lymphosarcomas, and among them there was an approximately 8.9% partial response rate in 158 patients who were treated with ACTH (adrenocorticotropic hormone) or adrenal steroids [72] . The next year, Kofman et al. reported objective regression of lymphomas in 53% of patients with the use of prednisone at dose schedules of 100 to 200 mg per day [73] .
Kyle et al. reviewed the results of 44 patients with malignant lymphoproliferative diseases treated with prednisone or prednisolone with dosages ranging from 50 to 150 mg daily for two to four weeks [74] . Peripheral lymphadenopathy decreased in 35 of 37 patients; splenomegaly was reduced in 27 of 29 patients; hemoglobin and platelet counts improved in 41 of 44 patients and 23 of 26 patients, respectively. Improvement of symptoms related to the lymphomas was seen in all patients. However, the benefit seen initially with the large dose of steroids could be sustained only by prolonging the treatment with a maintenance dose.
CHOP is still considered the gold standard treatment for intermediate and high-grade NHL, and is the most commonly used regimen for this disease. Discrepancies in steroid dosages used as part of the reported standard CHOP regimens are common and not well recognized in the medical literature. Although Table 4 may suggest similar response rates for intermediate/high-grade NHL treated with different prednisone dose schedules, we acknowledge that such a conclusion is probably unreachable from the current medical literature. A meta-analysis of these trials will not be able to analyze this data since these studies were conducted over a period of almost three decades, and during this time the histologic classification of lymphomas underwent several revisions as did the definition of response rates among the different studies. Also, the advent of more technologically advanced ancillary methods of diagnosis and the identification of prognostic factors have redefined the diagnosis and staging of patients with NHL. In Tables 2 and 3 we demonstrate that these CHOP regimens sometimes utilized not only different dosages of steroids, but also different dose schedules of the other chemotherapy agents. These changes should also be considered when analyzing the different outcomes. The reported response rates (with 95% confidence interval) and the number of patients in each study treated with CHOP for advanced aggressive NHL, is plotted in Table 5 . From this figure we conclude that variations in the dose of prednisone used does not seem to significantly change the response rate in patients with NHL. Based on this table and the above discussion we have left the final conclusions regarding any relationship between the different dosages of steroids and response rates to the interpretation of the reader. Several of our surveyed physicians questioned the real role of the steroids in the CHOP regimen for NHL. An interesting observation is that ABVD (ADR, bleomycin, vinblastine, and dacarbazine), the current gold standard regimen for the treatment of Hodgkin lymphomas, does not include steroids.
Contrary to the belief that the "standard" dose of steroids in the CHOP regimen is well known by most physicians, our survey demonstrated that a third of practicing hematologist and oncologist across the country were not aware of the discrepancies existing in the medical literature regarding the dose of prednisone in the CHOP regimen and that the steroid dosages currently being used vary widely from a "low dose" of 1 mg/kg/days 1-5 to the "high-dose schedule" of 100 mg/m 2 /days 1-5. Most of the reviewed CHOP clinical trials limit the toxicities reported to those typically seen with the cytotoxic agents, namely, myelosuppression, infections, cardiac effects, and treatment associated mortality. Adverse effects such as memory disturbances, mood changes, insomnia, gastritis, new onset of arterial hypertension or diabetes mellitus, steroid-related withdrawal syndrome, steroid myopathy, and incidence of osteoporosis are rarely described, although it is well known that these side effects are relatively frequent in patients taking large doses of steroids. The Boston Collaborative Drug Surveillance Program reported an 11.4% incidence of acute adverse reactions among 718 consecutively monitored hospitalized medical patients receiving a mean dose of 32.2 mg of prednisone per day [75] . Gastrointestinal symptoms were the most common acute reactions 246 Prednisone Dosage in the CHOP Regimen seen with the use of steroids. A striking correlation of acute psychiatric reactions with the dose of prednisone received was also found (incidence of 1.3% for patients receiving 40 mg/day, 4.6% for those receiving 41-80 mg/day, and 18.4% for those taking 80 mg/day or more). Forty percent of all the patients in this study were treated for neoplastic diseases. Sitzia et al. studied the side effects of CHOP in the treatment of NHL [76] . This 75-item self-report questionnaire showed that difficulty sleeping, feeling depressed, and weight gain occurred at an incidence of 56%, 45%, and 55%, respectively. These adverse effects are commonly seen with patients taking high doses of steroids. Nearly half of our surveyed physicians consider that their patients have to deal with clinically significant steroids-related side effects during their treatment with CHOP. Although some may argue that a 25% response rate to our survey was low, it is actually considered a good response by those currently conducting surveys via the internet. It must also be considered that a significant percentage of these e-mails were, for technical reasons, never delivered. Additionally, it was not targeted specifically to physicians whose practices are mostly limited to the treatment of lymphomas. However, more than half of the surveyed physicians has seen more than 10 NHL patients the prior year.
We believe that a prospective randomized trial will be able to answer these two important questions, "Does it make any difference what prednisone dose is utilized?" and "Can we spare our patients of the short-and long-term side effects of high-dose steroids without sacrificing the effectiveness of the CHOP regimen?" A trial comparing the two most common prednisone dosages used in the U.S. (100 mg/day for five days versus 100 mg/m 2 /day for five days) may prove that there are clinically significant differences in the efficacy and toxicities of these steroid dosages. Until such a study is performed and based on this retrospective review, a prednisone dose of 100 mg/day for five days should be considered the standard dose as part of the CHOP regimen. This dose is the most frequently reported, most referenced, and, based on this retrospective review, does not seem to be associated with a worse outcome than that seen in patients with intermediate/high-grade NHL treated with alternative prednisone dose schedules.
